Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Chief Scientific Officer | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 339,356 |
Reported balance
After 2026-02-13 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 240,000 · Balance 339,356 F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
| Common StockSEC Table I · non-derivative | Direct | 339,356 |
Reported balance
After 2026-02-14 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-02-14 · Exercise / conversion · Acquired 7,050 · Balance 339,356 F2: Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of RSUs. The grant of RSUs was initially reported in Table I of the Forms 4 filed by the Reporting Person on February 18, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 336,910 |
Reported balance
After 2026-02-14 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-02-14 · Tax withholding · Disposed 2,446 · Balance 336,910 F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
F2: Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of RSUs. The grant of RSUs was initially reported in Table I of the Forms 4 filed by the Reporting Person on February 18, 2025.
F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2026 Filed Feb 18, 2026 17:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 2,446 | $1.89 | $4,622.94 |
DisclosureSEC source: 0001470831-26-000179 · wk-form4_1771452309.xml · nonDerivative · entry 3 Mahaney Paige · CIK 0002040313 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,910 F3 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 17:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 7,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000179 · wk-form4_1771452309.xml · nonDerivative · entry 2 Mahaney Paige · CIK 0002040313 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of RSUs. The grant of RSUs was initially reported in Table I of the Forms 4 filed by the Reporting Person on February 18, 2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 17:05 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000179 · wk-form4_1771452309.xml · nonDerivative · entry 1 Mahaney Paige · CIK 0002040313 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,356 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 120,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 120,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Tax withholdingCommon Stock | 5,644 | $2.58 | $14,561.52 |
DisclosureSEC source: 0001193125-25-258664 · ownership.xml · nonDerivative · entry 2 Mahaney Paige · CIK 0002040313 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,356 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 19,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-258664 · ownership.xml · nonDerivative · entry 1 Mahaney Paige · CIK 0002040313 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on October 28, 2024. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 16:54 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 42,400 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001662579-25-000015 · wk-form4_1739915672.xml · derivative · entry 2 Mahaney Paige · CIK 0002040313 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,400 Underlying: Common Stock · 42,400 shares Expires 2035-02-13 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 16:54 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 28,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-25-000015 · wk-form4_1739915672.xml · nonDerivative · entry 1 Mahaney Paige · CIK 0002040313 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 16:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 345,600 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000094 · wk-form4_1730233884.xml · derivative · entry 2 Mahaney Paige · CIK 0002040313 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,600 Underlying: Common Stock · 345,600 shares Expires 2034-10-27 F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 28, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 16:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 76,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-24-000094 · wk-form4_1730233884.xml · nonDerivative · entry 1 Mahaney Paige · CIK 0002040313 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,800 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on October 28, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.